DK1767639T3 - Orale anti-leucocytozoonose-vacciner på basis af transgeniske planter - Google Patents

Orale anti-leucocytozoonose-vacciner på basis af transgeniske planter

Info

Publication number
DK1767639T3
DK1767639T3 DK05743390.6T DK05743390T DK1767639T3 DK 1767639 T3 DK1767639 T3 DK 1767639T3 DK 05743390 T DK05743390 T DK 05743390T DK 1767639 T3 DK1767639 T3 DK 1767639T3
Authority
DK
Denmark
Prior art keywords
leucocytozoonosis
transgenic plants
vaccines based
oral anti
chickens
Prior art date
Application number
DK05743390.6T
Other languages
English (en)
Inventor
Akira Ito
Toru Gotanda
Shigeki Kobayashi
Katsumi Kume
Takeshi Matsumura
Original Assignee
Kitasato Daiichi Sankyo Vaccine Co Ltd
Nat Inst Of Advanced Ind Scien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Daiichi Sankyo Vaccine Co Ltd, Nat Inst Of Advanced Ind Scien filed Critical Kitasato Daiichi Sankyo Vaccine Co Ltd
Application granted granted Critical
Publication of DK1767639T3 publication Critical patent/DK1767639T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DK05743390.6T 2004-05-31 2005-05-30 Orale anti-leucocytozoonose-vacciner på basis af transgeniske planter DK1767639T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004160666 2004-05-31
PCT/JP2005/009851 WO2005116216A1 (ja) 2004-05-31 2005-05-30 遺伝子組換え植物による抗原虫病経口ワクチン

Publications (1)

Publication Number Publication Date
DK1767639T3 true DK1767639T3 (da) 2012-06-11

Family

ID=35450895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05743390.6T DK1767639T3 (da) 2004-05-31 2005-05-30 Orale anti-leucocytozoonose-vacciner på basis af transgeniske planter

Country Status (8)

Country Link
US (1) US8617575B2 (da)
EP (1) EP1767639B1 (da)
JP (1) JP4898432B2 (da)
AT (1) ATE547526T1 (da)
AU (1) AU2005248233C1 (da)
CA (1) CA2567952C (da)
DK (1) DK1767639T3 (da)
WO (1) WO2005116216A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5343079B2 (ja) 2008-08-18 2013-11-13 北里第一三共ワクチン株式会社 トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法
US9181561B2 (en) * 2009-01-29 2015-11-10 Hokusan Co., Ltd. Adiponectin-containing eating behavior control agent for oral administration
US10154974B1 (en) 2015-10-16 2018-12-18 The Regents Of The University Of California Use of abscisic acid for the prevention and treatment of malaria
JP6999904B2 (ja) * 2016-09-05 2022-02-04 ホクサン株式会社 マラリア伝播阻止型ワクチン
CN110684097B (zh) * 2019-09-02 2023-11-10 佛山市正典生物技术有限公司 卡氏住白细胞虫重组r7蛋白及其制备方法和应用
CN110596400B (zh) * 2019-09-02 2023-04-07 佛山市正典生物技术有限公司 基于卡氏住白细胞虫重组r7蛋白的间接elisa检测方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929405T2 (de) * 1988-09-06 2003-02-06 Univ St Louis Orale-immunisierung durch verwendung von transgenen pflanzen
US20020006411A1 (en) * 1991-08-26 2002-01-17 Arntzen Charles Joel Vaccines expressed in plants
GB9403819D0 (en) * 1994-02-28 1994-04-20 Univ Leeds Control of parasites
JP3582663B2 (ja) * 1994-04-19 2004-10-27 社団法人日本動物用医薬品協会 鶏ロイコチトゾーン免疫原性蛋白質を発現する遺伝子クローン及び鶏ロイコチトゾーン症に対する遺伝子組換えワクチン
AU691707B2 (en) 1994-10-24 1998-05-21 The Administrators Of The Tulane Eductional Fund Oral immunization with transgenic plants
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
JP2002533068A (ja) * 1998-12-22 2002-10-08 ボイス トンプソン インスティテュート フォア プラント リサーチ トランスジェニック植物に発現される経口で免疫原性の細菌エンテロトキシン
ES2288882T3 (es) * 1999-10-26 2008-02-01 Plant Research International B.V. Glicosilacion de tipo mamifero en plantas.
JP4501801B2 (ja) 2005-07-15 2010-07-14 株式会社デンソーウェーブ 光学的情報読取装置

Also Published As

Publication number Publication date
JP4898432B2 (ja) 2012-03-14
US8617575B2 (en) 2013-12-31
CA2567952A1 (en) 2005-12-08
EP1767639A1 (en) 2007-03-28
EP1767639A4 (en) 2008-03-05
EP1767639B1 (en) 2012-02-29
AU2005248233B2 (en) 2010-02-18
AU2005248233C1 (en) 2010-08-19
AU2005248233A1 (en) 2005-12-08
ATE547526T1 (de) 2012-03-15
WO2005116216A1 (ja) 2005-12-08
JPWO2005116216A1 (ja) 2008-04-03
AU2005248233B8 (en) 2010-04-01
US20080003243A1 (en) 2008-01-03
CA2567952C (en) 2016-02-02

Similar Documents

Publication Publication Date Title
DK1767639T3 (da) Orale anti-leucocytozoonose-vacciner på basis af transgeniske planter
DK1881845T3 (da) Nipah-virusvacciner
DK2097102T3 (da) Kombinationsvaccine med reducerede mængder af poliovirusantigen
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
PH12020500101A1 (en) Novel muscosal adjuvants and delivery systems
EP4043031A3 (en) Zika viral antigen constructs
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
WO2007098717A3 (es) Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
DK1594543T3 (da) Hæmmer af immunogen vedhæftning og fremgangsmåde til fremstilling og anvendelse af deraf
BRPI0407727A (pt) adjuvante de vacina de linfócito humano
قيصر نعمة مظلوم الربيعي Effects of Laser Light on Vaccination with Hepatitis B Vaccine
JP2018531265A5 (da)
RU2002130182A (ru) Способ вакцинопрофилактики полиомиелита на крайнем севере
Petrovsky et al. New-age vaccine adjuvants: friend or foe? A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity
EA201991559A1 (ru) Конъюгаты полипептид-антиген с неприродными аминокислотами
Sadrzadeh et al. Infectious bursal disease-immune complex vaccine in broilers: immune response and pathological development
EA201270709A1 (ru) Композиции вакцины и способы их применения
RU2004130267A (ru) Способ вакцинации детей против краснухи на крайнем севере
RU2003101793A (ru) Штамм "52/70-м" вируса инфекционной бурсальной болезни для изготовления инактивированной вакцины и оценки их иммуногенности
Sontakke et al. Vaccines & Vaccination